NEW YORK, Jan. 13, 2015 /PRNewswire-USNewswire/ -- TB Alliance, an international not-for-profit organization with the mission of developing improved tuberculosis (TB) treatments, announced the appointment of Mario Raviglione, MD, director of the Global TB Programme at the World Health Organization (WHO), and Shalini Sharp, the chief financial officer of Ultragenyx Pharmaceutical Inc., to its Board of Directors.

OPBIO Factory Co., Ltd. (OPBIO) has signed a research agreement with the Global Alliance for TB Drug Development (TB Alliance). The research program involves the discovery of candidate compounds for tuberculosis (TB) drugs in partnership with TB Alliance.

NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment.

Pretomanid is a component of two new TB drug regimens being tested by TB Alliance for their ability to transform TB therapy, as well as future planned trials.

We need your input. Please join us at an event designed to get your feedback on formulation, color, pill burden, and other preferences for tomorrow’s TB drug regimens.

For the first time, the upcoming International AIDS Conference will feature a dedicated hub for discussing the deadly duo of TB-HIV.

TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, has announced that it is collaborating with, and has granted an exclusive license to, the Shanghai Fosun Pharmaceutical Development Co., Ltd., and its subsidiary Shenyang Hongqi Pharmaceutical Co., Ltd. (Fosun Pharma), to develop and commercialize the first-ever regimen designed to treat both drug-sensitive TB (DS-TB) and multi-drug resistant TB (MDR-TB) for use within People’s Republic of China, Taiwan, Hong Kong and Macau (Licensed Territory).

STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB.

You can see here details for an upcoming webinar by the TB Alliance on improving pediatric TB treatment (April 9).

Data will guide development of improved TB treatment for infants.